SPARTAN Trial Interim Results in Patients With IgAN

Interim results of the SPARTAN trial (NCT04663204), an open-label, single-arm, multicenter trial of sparsentan as first-line treatment for patients newly diagnosed with IgA nephropathy (IgAN), were reported during the National Kidney Foundation Spring Clinical Meetings 2025.

The study cohort included 12 patients aged 18 years and older with biopsy-proven IgAN. Eligible patients had proteinuria of 0.5 g/d or greater and estimated glomerular filtration rate of 30 mL/min/1.73 m² or greater and had not used angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for 12 months or longer before study enrollment.

Study participants received sparsentan for 110 weeks, followed by a 4-week safety period. Proteinuria, BP, body weight, total body water (bioimpedance), urinary soluble CD163 (inflammatory biomarker), and safety were assessed.

Reductions in proteinuria were rapid: –61.9% by week 4 and sustained over 24 weeks. Complete proteinuria remission was seen in 58% of patients at any time during treatment. After an initial decrease, BP was stable over 24 weeks. Total body water and body weight were generally stable. Rapid and sustained reductions in urinary soluble CD163 were observed.

One patient discontinued treatment due to hypertension. The most frequent adverse event was dizziness.

“Sparsentan as first-line treatment was generally well tolerated, with reductions in proteinuria approximately 70% and urinary soluble CD163 approximately 50% over 24 weeks,” the researchers said.

Source: Cheung CK, Moody S, Dhaun N, et al. Sparsentan (SPAR) as first-line treatment of incident patients with IgA nephropathy (IgAN): interim analysis of the SPARTAN trial. Abstract #G-452. Presented at the National Kidney Foundation Spring Clinical Meetings 2025; April 10-13, 2025; Boston, MA. doi:10.1053/j.ajkd.2025.02.453